21 16

The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study

Authors
 JianZhong Zhang  ;  Tsen-Fang Tsai  ;  Min-Geol Lee  ;  Min Zheng  ;  Gang Wang  ;  HongZhong Jin  ;  Jun Gu  ;  RuoYu Li  ;  QuanZhong Liu  ;  Jin Chen  ;  CaiXia Tu  ;  ChunMei Qi  ;  Hua Zhu  ;  William C. Ports  ;  Tim Crook 
Citation
 Journal of Dermatological Science, Vol.88(1) : 36-45, 2017 
Journal Title
 Journal of Dermatological Science 
ISSN
 0923-1811 
Issue Date
2017
MeSH
Administration, Oral ; Adult ; Asian Continental Ancestry Group ; China ; Double-Blind Method ; Female ; Humans ; Janus Kinases/antagonists & inhibitors ; Male ; Middle Aged ; Piperidines/therapeutic use* ; Protein Kinase Inhibitors/therapeutic use* ; Psoriasis/drug therapy* ; Pyrimidines/therapeutic use* ; Pyrroles/therapeutic use* ; Republic of Korea ; Severity of Illness Index ; Taiwan ; Treatment Outcome
Keywords
Asia ; Efficacy ; Janus kinase inhibitor ; Plaque psoriasis ; Safety ; Tofacitinib
Abstract
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor. OBJECTIVE: This study assessed tofacitinib efficacy and safety vs placebo in Asian patients with moderate to severe chronic plaque psoriasis. METHODS: Patients from China mainland, Taiwan, and Korea were randomized 2:2:1:1 to tofacitinib 5mg (N=88), tofacitinib 10mg (N=90), placebo→5mg (N=44), or placebo→10mg (N=44), twice daily (BID) for 52 weeks. Placebo-treated patients advanced to tofacitinib at Week 16. Co-primary efficacy endpoints: proportions of patients achieving Physician's Global Assessment (PGA) response ('clear' or 'almost clear') and proportion achieving ≥75% reduction from baseline Psoriasis Area and Severity Index (PASI75) at Week 16. RESULTS: At Week 16, more patients achieved PGA and PASI75 responses with tofacitinib 5mg (52.3%; 54.6%) and 10mg (75.6%; 81.1%) BID vs placebo (19.3%; 12.5%; all p<0.0001). Of patients with a Week 16 response, 73.6% and 75.0% maintained PGA response, and 76.8% and 84.9% maintained PASI75 to Week 52 with tofacitinib 5mg and 10mg BID, respectively. Over 52 weeks, 2.2-4.5% of patients across treatment groups experienced serious adverse events, and 1.1-6.8% discontinued due to adverse events. CONCLUSION: Tofacitinib demonstrated efficacy vs placebo at Week 16 in Asian patients with moderate to severe plaque psoriasis; efficacy was maintained through Week 52. No unexpected safety findings were observed. [NCT01815424].
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/160967
Files in This Item:
T201703728.pdf Download
DOI
10.1016/j.jdermsci.2017.05.004
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실)
Yonsei Authors
이민걸(Lee, Min Geol)
Export
RIS (EndNote)
XLS (Excel)
XML
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse